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Abstract
Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene leading to dystrophin deficiency, muscle fiber
degeneration and progressive fibrotic replacement of muscles. Givinostat, a histone deacetylase (HDAC) inhibitor, significantly reduced fibrosis
and promoted compensatory muscle regeneration in mdx mice. This study was conducted to evaluate whether the beneficial histological effects of
Givinostat could be extended to DMD boys. Twenty ambulant DMD boys aged 7 to <11 years on stable corticosteroid treatment were enrolled in
the study and treated for ≥12 months with Givinostat. A muscle biopsy was collected at the beginning and at the end of treatment to evaluate the
amount of muscle and fibrotic tissue. Histological effects were the primary objectives of the study. Treatment with Givinostat significantly
increased the fraction of muscle tissue in the biopsies and reduced the amount of fibrotic tissue. It also substantially reduced tissue necrosis and
fatty replacement. Overall the drug was safe and tolerated. Improvement in functional tests was not observed in this study, but the sample size of
the study was not sufficient to draw definitive conclusions. This study showed that treatment with Givinostat for more than 1 year significantly
counteracted histological disease progression in ambulant DMD boys aged 7 to 10 years.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Duchenne Muscular Dystrophy (DMD) is the most common
muscular dystrophy in childhood [1]. The disease is caused by
mutations in the dystrophin gene, leading to dystrophin
deficiency and subsequent cell membrane instability.
This instability determines uncontrolled calcium influx,
inflammation, necrosis, and replacement of muscle with fibrotic
tissue and fat, which leads to severe muscle wasting and
weakness.
Pharmacological blockade of the histone deacetylase
activity, which is constitutively active in DMD muscles [2] by
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HDAC inhibitors (HDACi), prevents fibrosis and promotes
compensatory regeneration in the mdx mouse, a model of DMD
[3,4].
Givinostat (aka ITF2357) is a potent HDACi currently being
developed for the treatment of DMD. In mdx mice [3],
Givinostat dose and concentration dependently increased
the cross-sectional area of myofibers, decreased the cellular
inflammatory infiltrate and prevented the formation of fibrotic
scars. These findings strongly suggested that in this DMD
animal model Givinostat was able to inhibit all the processes
which determine muscle fibrotic substitution (inflammation,
necrosis, fatty replacement and fibrosis) and to stimulate
muscle regeneration with the formation of larger muscle fibers
and overall more muscle tissue. Results also suggested that
exposures of Givinostat of 300 ng*h/mL are required to exert
the beneficial effect.
To evaluate the potential of Givinostat as a treatment for
DMD, we conducted the study summarized in this manuscript.
The primary objective of this study was to confirm also in
humans that Givinostat can counteract the histological signs of
the disease.
2. Methods
2.1. Patients
Twenty boys aged 7 to <11 years with an
immunohistochemical and molecular diagnosis of DMD were
enrolled in this study after an informed consent form was
signed by a parent/guardian and child had assented to be in
the study (if applicable). Boys were on a stable dose of
systemic corticosteroids for at least six months and were
able to complete the two screening 6 minute walk tests (6MWT)
with a minimal distance of at least 250 meters each with the
results of these tests within ± 30 meters of each other.
Exclusion criteria were aimed at avoiding confounding factors
from other potentially active treatments, and at recruiting
boys without significant co-morbidities and without clinical
alterations that could be worsened by Givinostat, e.g. low
platelet counts. Detailed inclusion/exclusion criteria are
summarized in the Supplementary Information.
2.2. Design
This was an open label two-part, phase 2 study. The primary
study objective was the evaluation of the histological effects
of Givinostat comparing baseline and end of treatment
muscle biopsies (brachial biceps). Secondary objectives of the
study were safety and tolerability, and functional assessments
(6MWT, North Star Ambulatory Assessment (NSAA) and
Performance of Upper Limb (PUL)).
Fig. 1 summarizes the study design. Part 1 was a dose
escalation study. Boys were asked to return to sites every week
for physical examination, vital signs, ECG, laboratory tests,
AEs collection, drug dispensing and PK sampling (only at
week 2).
All the boys who completed Part 1 entered Part 2. One boy
entered the study directly in Part 2. Boys visited their study
site at months 1, 2, 3, 4.5, 6, 7.5, 9, 10.5 and 12 of Part 2 for
physical examination, vital signs, ECG, laboratory tests, AEs
collection, drug dispensing and PK sampling (only at month
12). 6MWT, NSAA, and PUL were evaluated at screening, start
of part 2, and at months 3, 6 and 12. Echocardiogram and
spirometry were conducted at screening and at the end of part 2.
2.3. Standard protocol approvals, registrations and patient
consents
The study was sponsored by Italfarmaco S.p.A. (Milan,
Italy), performed in compliance with Good Clinical Practice
and the Declaration of Helsinki and it was registered (Identifier
NCT01761292) at www.Clinicaltrials.gov. The study was
approved by the local Ethics Committees and authorized by the
Competent Authority of Italy. A parent or guardian of the
participants provided informed written consent and each
subject provided written assent before participation.
2.4. Treatments
All boys were treated with Givinostat. During part 1 the dose
was escalated from 25 mg BID to 50 mg BID and then reduced
to 37.5 mg BID dose. During part 2 all boys were started on the
37.5 mg BID; seven completed the study on this dose and
twelve reduced the dose to 25 mg BID (see below for details).
All boys continued the steroid treatment regimen they were on
at screening.
2.5. Endpoints
Histology: the primary endpoint was the change in histology
comparing the brachial biceps biopsies before and after
≥12 months of treatment with Givinostat. The histological
parameters assessed were: muscle fiber area fraction (MFAF),
cross-sectional area (CSA), necrosis, hypercontracted (hyaline)
fibers, fatty replacement and fibrosis (total, endomysial,
perimysial). Details on muscle biopsy collection, preparation
and histological assessments are provided in the Supplementary
Information.
Muscle Function Tests: change in 6MWT, NSAA and PUL
after treatment with Givinostat were secondary endpoints.
Details on these function tests were reported previously [5–7].
Safety and tolerability were assessed by AEs collection,
laboratory tests, physical examination, vital signs, ECG,
echocardiogram and spirometry. The following laboratory
tests were performed: hematology, total bilirubin, alkaline
phosphatase, amylase, ALT, AST, LDH, C-reactive protein,
creatine kinase, total protein, albumin, uric acid, sodium,
potassium, chloride, calcium, glucose, creatinine, BUN, and
CPK, creatinine clearance, and urinalysis. Laboratory tests
were conducted at local laboratories.
2.6. Statistical analysis
Based on the results reported in the Desguerre publication
[8], a sample size of 20 boys completing the study provided a
90% power (at a 2-sided alpha level of 5%) to detect at least a
25% relative increase in MFAF between pre- and post-treatment
using a paired t-test and assuming a normal distribution.
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The histological parameters were analyzed on all boys who
completed the study, received at least 80% of the Givinostat
dose in Part 2, had one baseline and one post-baseline
assessment of biopsies, and had no major protocol violations.
The ITT population, including all boys enrolled in Part 1 or Part
2 of the study, was used for all the other assessments.
The statistical significance of the change from baseline to
the end of the study was tested by paired T-test. Normality
assumptions were confirmed by the Shapiro–Wilk test of
normality. All statistical tests were performed using a two-tailed
5% significance level.
Givinostat effect on fiber size was evaluated considering the
distribution of CSA before treatment (PRE) and at the end of
the study (POST). For each individual, PRE and POST CSA
values were normalized to the maximum PRE CSA value of
that individual. The pooled PRE and POST log-CSA values
histograms obtained after normalization and logarithmic
transformation were inspected to ascertain a possible shift
towards higher fiber size values in the POST distribution.
In particular, a common shape underlying the PRE and POST
distributions, differing just by a shift S in terms of fiber
size, was considered. The common shape was described as
a 2-component Gaussian mixture, whose parameters were
estimated by the Expectation–Maximization method. The value
of the shift S quantifies the effect of Givinostat on a generic
muscle fiber, whose size, after treatment, results K = exp(S)
times larger than the baseline value.
3. Results
The baseline characteristics of the 20 boys are summarized
in Fig. 1. In Part 1, four boys started at the 25 mg BID dose,
eight at the 50 mg BID dose and another seven boys at the
37.5 mg BID dose. Overall, Part 1 lasted 2 months. One of the
19 boys enrolled in Part 1 was discontinued from the study as he
reached a stopping rule (platelet counts <50 × 109/L) while on
treatment with Givinostat 50 mg BID. Another boy treated
with Givinostat 50 mg BID reached a stopping rule of
temporary treatment suspension (platelet counts <75 × 109/L
but >50 × 109/L). As a result and according to the predefined
rules to declare the Maximum Tolerated Dose the dose of 50 mg
BID was considered not tolerated. The remaining 18 boys and
one other boy entered in Part 2. The dose of 37.5 mg BID was
considered the Maximum Tolerated Dose and recommended
for Part 2. At the beginning of Part 2 some boys treated
at 37.5 mg BID had platelet reduction below the LLN but
never <75 × 109/L (temporary stopping criterion). Therefore,
the protocol was amended to require that platelet counts
be assessed ≥every 2 weeks in the first 2 months of therapy
Fig. 1. Study design and patient demography. Overall, Part 1 lasted 2 months, while part 2 lasted 12 months.
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at 37.5 mg BID and that the dose be lowered to 25 mg BID if
persistent platelet counts ≤150 × 109/L were observed.
Givinostat dose was maintained at 37.5 mg BID in 7 boys and
reduced to 25 mg BID in 12. All 19 boys who entered Part 2
completed that part of the study. End of study biopsy could not
be evaluated in one boy due to poor conditions of the tissue
collected.
All biopsies showed a negative immunoreaction for
dystrophin at baseline and end of study. Table 1 and Tables
S1–S2 summarize the histological results (Fig. S2 provides
examples of histological results). At baseline on average 46% of
the tissue samples were occupied by fibrosis, and 51% by
muscle. At the end of Part 2, there was a significant reduction
of necrotic and hyper contracted fiber number, fat tissue
replacement, and endomysial and perimysial fibrosis. MFAF
increased due to a homogeneous increment of the CSA value
of all fibers. Mean CSA increased by 77.7%. As shown in
Fig. 2, the distribution of log-transformed CSA had a
similar shape before and after treatment with Givinostat.
Treatment with Givinostat shifted the distribution to the right,
indicating a multiplicative increase in fiber size by a factor
K = exp(S) = 1.70 (p ≤ 0.001). K values were significantly
larger in boys treated with 37.5 mg BID throughout Part 2 of the
study compared to those who switched to the 25 mg BID dose
(Mean ± SD 37.5 mg BID (N = 7) = 2.11 ± 0.52; Mean ± SD
25 mg BID (N = 12) = 1.61 ± 0.37, p < 0.05). Histological
parameters did not correlate with either age or steroid
treatment duration either at baseline or at the end of Part 2
(age: R = −0.18 to 0.43, NS; steroid duration: R −0.16 to 0.34,
NS).
Three serious AEs were reported during the study (platelet
reduction, rhabdomyolysis during muscle biopsy anesthesia,
tibioperoneal fracture). Only the Platelet reduction was
considered drug related (dose: 50 mg BID) and led to study
discontinuation. All AEs were mild to moderate in intensity
except for the aforementioned serious AEs and a platelet and
neutrophil decrease (drug related) in Part 2. Table 2 summarizes
the drug related AEs reported in Part 1 (Table 2A) and Part 2
(Table 2B) by more than 1 boy.
Platelet decrease and diarrhea were the most frequent AEs in
the study. In Part 1, white blood cell decreased and most of the
platelet decreased was reported only at the 50 mg BID dose. In
Part 2, platelet decrease has been reported more frequently,
with the 37.5 mg BID dose (63.2% vs 41.7%). Givinostat
treatment was not associated to any other clinically significant
laboratory abnormality. Similarly, vital signs, FEV1, FVC,
FEV1/FVC, PEF and ECGs were not significantly altered.
Table 3 reports the results in the functional tests. One
child could not complete the 6MWT at month 12 due to a
tibioperoneal fracture at month 6. MFAF (directly) and total
fibrosis (indirectly) correlated with the 6MWT at baseline and
end of study. MFAF and Total Fibrosis correlated also with
NSAA total score at baseline and with time to rise from floor at
the end of the study (Table S3).
Pharmacokinetic analyses indicated that following oral
BID administration givinostat plasma exposures were dose-
proportional. Cmax was observed at 2 to 4 hours post-dosing
(median) at all doses administered. At all dose levels, the
variability of plasma PK parameters was limited. Givinostat
was at steady-state following 7 days of administration.
Analysis of the accumulation ratios suggested a slight reduction
(approximately 30%) at the end of the study compared to the
results obtained following one week of treatment.
4. Discussion
While other treatments have previously shown to partially
restore dystrophin [9,10], this is the first time that a
pharmacological treatment was shown to produce beneficial
Table 1
Histological parameters at baseline and end of study and absolute and relative change.
Baseline
Mean ± SD
End of Study
Mean ± SD
Absolute Change
Mean (95% CI)
Relative Change
MFAF (%) 51.00 ± 9.61 64.91 ± 8.35 13.91
(11.57, 16.25; p < 0.0001)
29.1%
• Deletions:13.25(10.16, 16.33; p < 0.0001) • Deletions:27.1%
• Duplications:11.42(5.30, 17.54; p = 0.0095) • Duplications:20.0%
• Point Mutations:17.08(10.15, 24.00; p = 0.0024) • Point Mutations:39.6%
CSA (μm2)* 1191.09 ± 400.98 2056.36 ± 781.39 865.27 ± 555.35
(p < 0.0001)
77.7%
Hypercontracted Fibers 1.98 ± 0.71 0.77 ± 0.54 −1.20
(−1.53, −0.87; p < 0.0001)
−60.4%
Total Fibrosis (%) 46.13 ± 9.61 33.49 ± 8.24 −12.64
(−14.95, −10.33; p < 0.0001)
−27.4%
Endomysial Fibrosis (%) 22.66 ± 6.51 17.60 ± 3.69 −5.06
(−8.17, −1.95; p= 0.0032)
−18.48%
Perimysial Fibrosis (%) 23.47 ± 8.66 15.88 ± 5.56 −7.59
(−10.81, −4.36; p= 0.0001)
−27.3%
Necrosis (%) 1.98 ± 0.73 1.02 ± 0.32 −0.96
(−1.28, −0.65; p < 0.0001)
−43.5%
Fatty Replacement (%) 0.89 ± 0.70 0.58 ± 0.60 −0.30
(−0.44, −0.17; p= 0.0002)
−37.5%
* Absolute change is mean ± SD.
646 P. Bettica et al. /Neuromuscular Disorders 26 (2016) 643–649
histological effects in muscles of DMD patients, though a
functional benefit could not be definitively assessed due to the
small sample size. Previous studies on muscle biopsies in DMD
[8,11] suggest that reductions in necrosis, fatty replacement and
fibrosis and increase in muscle fiber area fraction do not occur
with disease progression in boys seven to ten years of age. This
is also supported by recent data with MRI and MRS that show
a progressive tissue damage in boys with DMD five years and
older [12]. Thus these histological effects are attributable to
Givinostat. The role of Givinostat treatment is further supported
by the lack of correlation between MFAF and total fibrosis and
either age or steroid treatment duration. Since Givinostat acts
on the pathogenetic events downstream of the genetic defects,
Givinostat is potentially a treatment for the whole DMD
population. The similar results in boys with deletions,
duplications or point mutations support this conclusion.
Fig. 2. Comparison of the estimated distributions of normalized log-CSA values measured in the biopsies before treatment (PRE) and at the end of part 2 (POST).
In the inset, the estimated distributions are superimposed on the pooled histograms.
Table 2
Drug related Treatment Emergent Adverse Events (TEAEs) that occurred in more than 1 patient during the Part 1 of the study (A) and during the Part 2 of the study
(B).
A 25.0 mg BID
(N = 4)
37.5 mg BID
(N = 7)
50.0 mg BID
(N = 12)
Overall
(N = 19)
Number (%) of Patients with drug related TEAEs 3 (75.0%) 6 (85.7%) 12 (100%) 18 (94.7%)
Abdominal pain 0 (0.0%) 2 (28.6%) 1 (8.3%) 3 (15.8%)
Diarrhea 2 (50.0%) 3 (42.9%) 5 (41.7%) 8 (42.1%)
Feces soft 0 (0.0%) 1 (14.3%) 1 (8.3%) 2 (10.5%)
Platelet decreased 0 (0.0%) 1 (14.3%) 7 (58.3%) 8 (42.1%)
White blood cell count decreased 0 (0.0%) 0 (0.0%) 4 (33.3%) 4 (21.1%)
Rash 1 (25.0%) 0 (0.0%) 1 (8.3%) 2 (10.5%)
B 25.0 mg BID
(N = 12)
37.5 mg BID
(N = 19)
Overall
(N = 19)
Number (%) of Patients with drug related TEAEs 9 (75.0%) 18 (94.7%) 18 (94.7%)
Abdominal pain 0 (0.0%) 5 (26.3%) 5 (26.3%)
Diarrhea 6 (50.0%) 9 (47.4%) 11 (57.9%)
Vomiting 1 (8.3%) 2 (10.5%) 3 (15.8%)
Platelet decreased 5 (41.7%) 12 (63.2%) 12 (63.2%)
Decreased appetite 2 (16.7%) 4 (21.1%) 6 (31.6%)
Headache 1 (8.3%) 1 (5.3%) 2 (10.5%)
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The mechanism of action at the basis of these histological
changes induced by Givinostat is still not fully elucidated.
However, it is already evident that Givinostat treatment is
followed by a homogeneous increase in muscle fibers size
(Fig. 2). Although follistatin and myostatin levels and/or
their downstream effects could not be assessed in the muscle
biopsies in this study, HDACi have been previously shown to
increase follistatin translation [4,13]. Follistatin down regulates
myostatin a major inhibitor of muscle fibers regeneration
[14–16] and in nature myostatin defects are accompanied by
large muscle mass. Future studies will need to clarify the role
of follistatin translation in the effects on muscle fiber size
observed with Givinostat.
The other key objective of this study was to confirm that
doses determining a significant histological effect were
also tolerated in boys with DMD. Platelet reductions and
gastrointestinal AEs have been the most frequent AEs in this
study. Platelet reduction has been observed with all HDACi
tested so far including Givinostat and it is considered related to
their pharmacological effect [17]. In this study, platelet
reduction, which met predefined stopping rules, were observed
only at 50 mg BID, a dose considered not tolerable. In Part 2,
platelet counts remained within the normal range after
treatment with 37.5 mg BID in 7 boys, while in other 12 the
dose was lowered to 25 mg BID to maintain platelet counts
within the normal range. The decision to lower the dose was
made even if no clinical manifestation of low platelet counts
(e.g. hemorrhage, petechiae, etc.) was observed.
In this study we wanted to maintain exposures to Givinostat
as high as possible to maximize the chances of seeing a
histological benefit. Using a starting dose of 37.5 mg BID
and applying the dose adjustment rules described in the
Results section met the objective of maintaining high exposures
without abnormal platelet counts. However, the dose was
reduced to 25 mg BID in 2/3 of patients. Significant
histological improvements were observed in all children in
Part 2, regardless of their dose. However, CSA increased
significantly more in boys treated at the highest dose throughout
part 2. As CSA fibers enlargement appears to be a key event in
the Givinostat effect, this result suggests that even if exposures
obtained after the 25 mg BID dose are efficacious, there is a
potential benefit in trying to maintain Givinostat exposures
as high as possible. Further studies will confirm if larger
Givinostat exposures are beneficial and if the dose adjustment
rules adopted in this study will allow maintaining platelet
counts stable and within normal ranges also in larger cohorts of
DMD patients.
Diarrhea was frequently reported in this study, but was mild
or moderate, never required treatment adjustments and never
led to drug discontinuation, suggesting that this AE is quite
manageable.
This study was not designed to assess efficacy and functional
tests were performed to evaluate possible negative effects
on muscle function. The changes in the function tests were
relatively small and similar to those expected in a DMD
population similar to the one in this study [18–20]. Because of
the small sample size and of the lack of a control group, no
further considerations can be made on the Givinostat effects on
muscle function. The significant correlation between the MFAF
and total fibrosis and most of the functional tests, however,
suggests that the histological improvements observed with
Givinostat may eventually lead to a functional benefit.
This study has challenges and limitations. Muscle biopsies
are always a challenge. A very tight control was maintained
throughout the study on muscle biopsy collection, transport,
processing and analysis. As a result only 1 biopsy was
considered not suitable for analysis. In our study the
histological and morphological analysis was performed to the
best standards following well documented identification criteria
typical of DMD skeletal muscle alterations [21], and
morphological analysis was carried out using MetaMorph, a
recognized reliable software. In fact, our baseline results are in
line with the results previously reported [8,22]. This study did
not include a control group, since it was not considered ethical
to have a group of boys on placebo undergoing 2 biopsies
without any chance of a potential treatment benefit. However, as
no histological improvements are expected in a group of DMD
boys aged seven to ten years, the significant histological results
obtained in this study are not affected by the lack of a control
group. Even if the patient number was small, the study was fully
powered to show an increase in MFAF at least as large as the
one observed in the preclinical study [3].
In conclusion, this study shows that administration of
Givinostat for more than one year significantly counteracts
histological disease progression in ambulant DMD boys aged
seven to ten years. These results support further development of
Givinostat in DMD.
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